SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues.
暂无分享,去创建一个
E. Giné | E. Campo | W. Huber | E. Haralambieva | S. Beà | H. Moch | O. Bernard | T. Zenz | Junyan Lu | M. Manz | M. Hensel | F. Nadeu | E. Marques Maggio | M. Bühler | D. Roos-Weil | T. Thavayogarajah | S. Scheinost
[1] A. Rosenwald,et al. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial , 2020, International journal of cancer.
[2] E. Giné,et al. Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes. , 2020, Blood.
[3] A. Schuh,et al. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP , 2020, Cell reports.
[4] D. Rossi,et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.
[5] L. Kaderali,et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML , 2019, Nature Communications.
[6] Andrzej K. Oleś,et al. Supplementary figures and tables , 2017 .
[7] R. Siebert,et al. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia , 2018, Blood Cancer Journal.
[8] Allyson E. Koyen,et al. SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. , 2017, Cell reports.
[9] L. Kaderali,et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia , 2016, Nature Medicine.
[10] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[11] S. Malek,et al. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.
[12] A. López-Guillermo,et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.
[13] F. Lasitschka,et al. SAMHD1's protein expression profile in humans , 2015, Journal of leukocyte biology.
[14] D. Bentley,et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.
[15] Jonathan C. Fuller,et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response , 2009, Nature Genetics.